JP2017510595A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510595A5
JP2017510595A5 JP2016560952A JP2016560952A JP2017510595A5 JP 2017510595 A5 JP2017510595 A5 JP 2017510595A5 JP 2016560952 A JP2016560952 A JP 2016560952A JP 2016560952 A JP2016560952 A JP 2016560952A JP 2017510595 A5 JP2017510595 A5 JP 2017510595A5
Authority
JP
Japan
Prior art keywords
carboxamide
anilino
dihydropyrimido
indolizine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560952A
Other languages
English (en)
Japanese (ja)
Other versions
JP6518690B2 (ja
JP2017510595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/056839 external-priority patent/WO2015155042A1/en
Publication of JP2017510595A publication Critical patent/JP2017510595A/ja
Publication of JP2017510595A5 publication Critical patent/JP2017510595A5/ja
Application granted granted Critical
Publication of JP6518690B2 publication Critical patent/JP6518690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560952A 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン Active JP6518690B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734.8 2014-04-07
EP14163734 2014-04-07
EP15153207.4 2015-01-30
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
JP2017510595A JP2017510595A (ja) 2017-04-13
JP2017510595A5 true JP2017510595A5 (en:Method) 2018-05-17
JP6518690B2 JP6518690B2 (ja) 2019-05-22

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560952A Active JP6518690B2 (ja) 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン

Country Status (16)

Country Link
US (3) USRE50082E1 (en:Method)
EP (1) EP3129374B1 (en:Method)
JP (1) JP6518690B2 (en:Method)
KR (1) KR102432420B1 (en:Method)
CN (1) CN106132963B (en:Method)
AU (1) AU2015243694B2 (en:Method)
BR (1) BR112016022342B1 (en:Method)
CA (1) CA2944610C (en:Method)
DK (1) DK3129374T3 (en:Method)
ES (1) ES2716165T3 (en:Method)
HU (1) HUE043108T2 (en:Method)
MX (1) MX368767B (en:Method)
PL (1) PL3129374T3 (en:Method)
PT (1) PT3129374T (en:Method)
RU (1) RU2692479C2 (en:Method)
WO (1) WO2015155042A1 (en:Method)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132963B (zh) * 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪
ES2966392T3 (es) * 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
CN109071542B (zh) * 2016-02-19 2021-07-20 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
KR20210019607A (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
NZ758458A (en) 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
JP2022520382A (ja) 2019-02-11 2022-03-30 フェニックス モレキュラー デザインズ Rsk阻害剤の結晶形態
US20250049801A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
JP2024544083A (ja) * 2021-12-15 2024-11-27 シルラジェン,インコーポレイテッド 修飾ベータ-シクロデキストリンを含む医薬組成物
JP2024546977A (ja) * 2021-12-15 2024-12-26 シルラジェン,インコーポレイテッド 新生物疾患の処置方法
MX2024010802A (es) * 2022-03-04 2024-09-11 Sillajen Inc Combinaciones farmaceuticas para uso en el tratamiento de enfermedades neoplasicas.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466243A1 (en) * 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
CA2526578C (en) 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2008065054A1 (en) 2006-11-28 2008-06-05 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
CN102076689B (zh) * 2008-06-26 2014-10-15 内尔维阿诺医学科学有限公司 吡唑并-喹唑啉类
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
EP2459196B1 (en) 2009-07-29 2015-09-09 Nerviano Medical Sciences S.r.l. Plk inhibitor salts
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
WO2012101032A1 (en) 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fshrの調節剤としてのイミダゾール化合物及びその使用
CN106132963B (zh) * 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪

Similar Documents

Publication Publication Date Title
JP2017510595A5 (en:Method)
CA2934137C (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2015514808A5 (en:Method)
EP3555074B1 (en) Aminopyrazoles as selective janus kinase inhibitors
PH12018500765A1 (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
JP2005539012A5 (en:Method)
JP2017502940A5 (en:Method)
IL279800B1 (en) Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
JP2019505541A5 (en:Method)
JP2021509113A (ja) キナーゼ阻害剤としての複素環式アミド
JP2005538099A5 (en:Method)
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
JP2018507877A5 (en:Method)
JP2006524669A5 (en:Method)
JP2010526129A5 (en:Method)
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
EA024406B1 (ru) АМИНОСПИРТ-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ХИНАЗОЛИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
CN115443276B (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
JP2017525668A5 (en:Method)
JP2017521407A5 (en:Method)
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
JP2015505301A5 (en:Method)
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
CA3095233A1 (en) 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders